Why Should Lives Be Lost When
Early Detection Can Save Them?
Nearly 10 million lives are lost each year to late-stage cancer.¹
PanGIA Biotech is changing that with non-invasive diagnostics that make early detection accessible to all.
↓ Read On To Learn How We Are Doing This. ↓
PanGIA BioTech:
Where Innovation Meets Compassion
At PanGIA Biotech, we believe early detection is the key to curing cancer.
Our mission is to revolutionize cancer detection with the true liquid biopsy, enabled by the PanGIA Analysis System (PAS).
We’re creating a world where detection is accurate, non-invasive, and accessible—powered by AI and grounded in rigorous science.
Our diagnostics are designed to support clinicians, serve patients, and bridge healthcare gaps globally.
With clinical use already underway outside the U.S. and regulatory pathways progressing at home, our priority remains: ensuring safety, efficacy, and access for the people who need it most.
Breaking Barriers in Cancer Detection
Despite progress, early diagnosis is often delayed by avoidable obstacles:
-
Invasive Procedures
Painful tests like biopsies or endoscopies deter screening—especially in underserved or culturally sensitive communities. -
Limited Access
Insurance gaps, distance from care, and lack of primary providers prevent timely diagnosis. -
System Barriers
Red tape, policy gaps, and referral delays add risk. -
Cultural & Communication Gaps
Stigma, language, and weak patient-provider communication reduce participation in screening. -
Slow Results
Long wait times for answers delay care and increase anxiety.
PanGIA Biotech exists to remove these barriers.
By replacing invasive procedures with fast, AI/ML-powered urine diagnostics, we deliver earlier answers—making detection easier, faster, and more equitable.
Our Journey to Impact
From an idea to save lives to a global mission, PanGIA Biotech’s story is one of innovation, collaboration, and perseverance:
Each step brings us closer to making early detection routine—and accessible worldwide.
Our Guiding Principles
- Innovation: Advancing cancer detection with non-invasive, scientifically validated solutions.
- Accessibility: Expanding diagnostic access to underserved regions and communities.
- Collaboration: Partnering with researchers, clinicians, and institutions to drive meaningful change.
These values keep us focused on improving lives with integrity and purpose.
References:
- World Health Organization. Global cancer burden growing amidst mounting need for services. Published February 1, 2024. Accessed December 28, 2024. https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing–amidst-mounting-need-for-services
- Lim FB, Lei T, Fernandez G, et al. A colorimetric chemical tongue detects and distinguishes between multiple analytes. Analyst. 2022;147(23):5283-5292. doi:10.1039/d2an01615J.